D.E. Shaw & Co’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-8,000
| Closed | -$1.23M | – | 4891 |
|
|
2025
Q4 | $1.1M | Buy |
8,000
+3,294
| +70% | +$431K | ﹤0.01% | 3473 |
|
|
2025
Q3 | $603K | Sell |
4,706
-7,866
| -63% | -$960K | ﹤0.01% | 3763 |
|
|
2025
Q2 | $1.52M | Sell |
12,572
-23,380
| -65% | -$2.64M | ﹤0.01% | 2940 |
|
|
2025
Q1 | $4.01M | Sell |
35,952
-576,427
| -94% | -$61.4M | ﹤0.01% | 2065 |
|
|
2024
Q4 | $59.6M | Buy |
612,379
+563,955
| +1,165% | +$60.1M | 0.04% | 496 |
|
|
2024
Q3 | $5.57M | Buy |
48,424
+45,588
| +1,607% | +$5.17M | ﹤0.01% | 1861 |
|
|
2024
Q2 | $302K | Buy |
+2,836
| New | +$285K | ﹤0.01% | 3884 |
|
|
2024
Q1 | – | Sell |
-54,817
| Closed | -$5.62M | – | 4612 |
|
|
2023
Q4 | $5.53M | Sell |
54,817
-70,106
| -56% | -$6.77M | ﹤0.01% | 1825 |
|
|
2023
Q3 | $12.7M | Sell |
124,923
-142,019
| -53% | -$14.4M | 0.01% | 1115 |
|
|
2023
Q2 | $26.9M | Buy |
266,942
+264,142
| +9,434% | +$26.4M | 0.03% | 720 |
|
|
2023
Q1 | $258K | Sell |
2,800
-20,643
| -88% | -$1.8M | ﹤0.01% | 3805 |
|
|
2022
Q4 | $2.13M | Buy |
23,443
+16,678
| +247% | +$1.4M | ﹤0.01% | 2897 |
|
|
2022
Q3 | $514K | Sell |
6,765
-236,647
| -97% | -$19.6M | ﹤0.01% | 4027 |
|
|
2022
Q2 | $20.6M | Sell |
243,412
-236,477
| -49% | -$20.7M | 0.02% | 855 |
|
|
2022
Q1 | $42.1M | Sell |
479,889
-1,340,015
| -74% | -$116M | 0.04% | 571 |
|
|
2021
Q4 | $159M | Buy |
1,819,904
+1,793,934
| +6,908% | +$149M | 0.13% | 159 |
|
|
2021
Q3 | $2.12M | Buy |
25,970
+15,329
| +144% | +$1.38M | ﹤0.01% | 2987 |
|
|
2021
Q2 | $971K | Buy |
+10,641
| New | +$948K | ﹤0.01% | 3569 |
|
|
2020
Q4 | – | Sell |
-37,158
| Closed | -$3.25M | – | 4095 |
|
|
2020
Q3 | $3.23M | Buy |
37,158
+5,943
| +19% | +$515K | ﹤0.01% | 2018 |
|
|
2020
Q2 | $2.73M | Sell |
31,215
-331,035
| -91% | -$28.6M | ﹤0.01% | 2152 |
|
|
2020
Q1 | $29.9M | Buy |
362,250
+354,885
| +4,819% | +$31.7M | 0.05% | 454 |
|
|
2019
Q4 | $697K | Buy |
+7,365
| New | +$661K | ﹤0.01% | 3220 |
|
|
2019
Q2 | – | Sell |
-103,545
| Closed | -$8.92M | – | 3801 |
|
|
2019
Q1 | $8.92M | Sell |
103,545
-703,162
| -87% | -$56.4M | 0.01% | 1172 |
|
|
2018
Q4 | $62M | Buy |
806,707
+587,157
| +267% | +$45.7M | 0.09% | 278 |
|
|
2018
Q3 | $16.9M | Sell |
219,550
-955,246
| -81% | -$70.6M | 0.02% | 848 |
|
|
2018
Q2 | $79.5M | Buy |
1,174,796
+1,144,940
| +3,835% | +$79M | 0.1% | 232 |
|
|
2018
Q1 | $2.16M | Buy |
+29,856
| New | +$2.27M | ﹤0.01% | 1998 |
|
|
2017
Q4 | – | Sell |
-131,929
| Closed | -$10.1M | – | 3692 |
|
|
2017
Q3 | $10.1M | Buy |
+131,929
| New | +$9.96M | 0.02% | 939 |
|
|
2017
Q2 | – | Sell |
-169,776
| Closed | -$11.3M | – | 3494 |
|
|
2017
Q1 | $11.3M | Sell |
169,776
-154,672
| -48% | -$10.3M | 0.02% | 833 |
|
|
2016
Q4 | $21.2M | Buy |
324,448
+59,937
| +23% | +$3.89M | 0.04% | 600 |
|
|
2016
Q3 | $18.7M | Sell |
264,511
-44,845
| -14% | -$3.27M | 0.03% | 603 |
|
|
2016
Q2 | $22.9M | Sell |
309,356
-651,581
| -68% | -$45M | 0.04% | 503 |
|
|
2016
Q1 | $62.4M | Buy |
960,937
+511,814
| +114% | +$34.8M | 0.11% | 214 |
|
|
2015
Q4 | $34.6M | Buy |
449,123
+443,208
| +7,493% | +$35.2M | 0.05% | 416 |
|
|
2015
Q3 | $487K | Sell |
5,915
-4,217
| -42% | -$375K | ﹤0.01% | 3071 |
|
|
2015
Q2 | $893K | Sell |
10,132
-3,260
| -24% | -$299K | ﹤0.01% | 2786 |
|
|
2015
Q1 | $1.18M | Buy |
+13,392
| New | +$1.19M | ﹤0.01% | 2434 |
|
|
2014
Q2 | – | Sell |
-28,317
| Closed | -$2.23M | – | 4429 |
|
|
2014
Q1 | $2.16M | Sell |
28,317
-70,041
| -71% | -$5.1M | ﹤0.01% | 2308 |
|
|
2013
Q4 | $7.08M | Buy |
98,358
+30,693
| +45% | +$2.13M | 0.01% | 1405 |
|
|
2013
Q3 | $4.65M | Sell |
67,665
-94,317
| -58% | -$6.24M | 0.01% | 1662 |
|
|
2013
Q2 | $10.3M | Buy |
+161,982
| New | +$10.5M | 0.02% | 852 |
|
Other funds holding NVS
D.E. Shaw & Co's NVS Position: Q1 2026 in Review
D.E. Shaw & Co sold out of Novartis (NVS) in Q1 2026, closing a stake of 8,000 shares — an estimated $1.23M sold.
D.E. Shaw & Co first reported a position in NVS in Q2 2013 and held it in 41 quarters. The position peaked at $159M in Q4 2021. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- D.E. Shaw & Co reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
- D.E. Shaw & Co sold 8,000 Novartis shares in Q1 2026, an estimated $1.23M.
- D.E. Shaw & Co first reported a position in Novartis in Q2 2013 and held it in 41 quarters.
- D.E. Shaw & Co's Novartis position peaked at $159M in Q4 2021.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.